Dulozetine HCL in Patients with Central Neuropathic Pain Due to Multiple
Sclerosis (MS)
Trial Status
Open for Enrollment
What is the Purpose of this Study?
To evaluate Duloxetine HCL (Cymbalta) for the management of central neuropathic
pain due to Multiple Sclerosis (MS).
Who is Eligible to Participate?
Patients 18 years or older with central neuropathic pain due to MS and
who do not meet any exclusionary criteria which will be addressed in further
detail by study coordinator.
What is involved in this Study?
Pain scores and patient questionnaires will be administered to patients
to determine the impact of treatment with Cymbalta versus placebo. Patients
will be randomized in a 1:1 treatment fashion to either Cymbalta 60 mg/d or
placebo for 6 weeks. Patients who complete the 6 week double blind period
will have the opportunity to participate in a 12 week open label study where
all patients will receive Cymbalta at different doses.
How long is the Study?
The study will be approximately 20 weeks with up to 18 weeks of treatment
For More Information Contact: Lynne E. Flynn, CCRC, study coordinator, at
602-258-2863 or lynneflynn@pnal.net or call the Main line at 602-258-3354
|
